AROMASIN FOR BREAST CANCER
Aromasin (exemestane) is an aromatase inactivator (AI). It disables aromatase enzyme which is required to produce estrogen in post-menopausal women. Target patient is in early stage of breast cancer, age post menopause, estrogen-receptor positive, and has undergone tamoxifen therapy for at least 2 years. Dosage is one tablet (25mg) once daily with a meal. Side effects include hot flushes, diarrhea, alopecia, ischemic cardiac events, hypercholesterolemia, osteoporosis.